Teleflex Incorporated (NYSE:TFX) insider Thomas E. Powell sold 5,200 shares of the company’s stock in a transaction on Friday, October 12th. The shares were sold at an average price of $246.84, for a total value of $1,283,568.00. Following the transaction, the insider now directly owns 15,351 shares in the company, valued at $3,789,240.84. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

TFX stock opened at $248.87 on Thursday. Teleflex Incorporated has a fifty-two week low of $227.52 and a fifty-two week high of $288.78. The company has a debt-to-equity ratio of 0.88, a quick ratio of 1.45 and a current ratio of 2.21. The stock has a market capitalization of $12.19 billion, a price-to-earnings ratio of 29.63, a PEG ratio of 1.87 and a beta of 1.12.

Teleflex (NYSE:TFX) last posted its earnings results on Thursday, August 2nd. The medical technology company reported $2.47 earnings per share for the quarter, beating analysts’ consensus estimates of $2.41 by $0.06. Teleflex had a return on equity of 17.32% and a net margin of 3.78%. The company had revenue of $609.87 million for the quarter, compared to the consensus estimate of $615.97 million. During the same quarter in the prior year, the company earned $2.04 earnings per share. Teleflex’s revenue was up 15.4% on a year-over-year basis. On average, equities analysts predict that Teleflex Incorporated will post 9.82 earnings per share for the current year.

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Summit Trail Advisors LLC raised its stake in shares of Teleflex by 23,599.0% in the first quarter. Summit Trail Advisors LLC now owns 1,181,159 shares of the medical technology company’s stock worth $1,181,000 after buying an additional 1,176,175 shares during the period. Bank of New York Mellon Corp raised its stake in shares of Teleflex by 0.3% in the second quarter. Bank of New York Mellon Corp now owns 548,319 shares of the medical technology company’s stock worth $147,064,000 after buying an additional 1,783 shares during the period. Marshall Wace LLP raised its stake in shares of Teleflex by 1,177.7% in the second quarter. Marshall Wace LLP now owns 342,631 shares of the medical technology company’s stock worth $91,897,000 after buying an additional 315,814 shares during the period. Morgan Stanley raised its stake in shares of Teleflex by 4.3% in the second quarter. Morgan Stanley now owns 292,030 shares of the medical technology company’s stock worth $78,325,000 after buying an additional 12,068 shares during the period. Finally, Jennison Associates LLC bought a new position in shares of Teleflex in the second quarter worth about $60,706,000. 88.89% of the stock is currently owned by hedge funds and other institutional investors.

A number of research analysts have weighed in on the company. Needham & Company LLC lowered their target price on Teleflex from $298.00 to $279.00 and set a “buy” rating on the stock in a report on Friday, August 3rd. Barclays assumed coverage on Teleflex in a report on Monday. They issued an “equal weight” rating and a $266.00 target price on the stock. ValuEngine downgraded Teleflex from a “buy” rating to a “hold” rating in a report on Friday, August 3rd. TheStreet downgraded Teleflex from a “b” rating to a “c+” rating in a report on Friday, August 3rd. Finally, Morgan Stanley lowered their target price on Teleflex from $310.00 to $295.00 and set an “overweight” rating on the stock in a report on Friday, August 3rd. Three research analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the stock. The company currently has an average rating of “Buy” and an average price target of $286.67.

About Teleflex

Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. It offers vascular access products that comprise Arrow branded catheters and related devices, including catheter positioning systems for use in the administration of intravenous medications and other therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site; and devices for treating coronary and peripheral vascular disease.

Featured Article: Put Option

Insider Buying and Selling by Quarter for Teleflex (NYSE:TFX)

Receive News & Ratings for Teleflex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teleflex and related companies with MarketBeat.com's FREE daily email newsletter.